20.5805.07% ( -1.100 )
Delay Closed: Nov 13, 16:08:17Valuation
Current ValuationThe current P/E ratio is -16.27, above the reasonable range, cheaper than 17.48% of the time in the past 1 years, and the industry ranks 56/78, the industry Median -5.30.
-16.27xP/E
HK$20.58Stock price
HK$-1.26Earnings per share
-16.27xP/E
Stock priceHK$20.58Earnings per shareHK$-1.26
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -22.45x
- Typical range
- -56.31x–-16.45x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0154308462616
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
09926HKAKESO | -69.56x | 75.50% | HK$77.46B |
09688HKZAI LAB | -16.36x | 17.69% | HK$25.47B |
01877HKJUNSHI BIO | -33.41x | 83.59% | HK$15.35B |
02627HKAB&B BIO-TECH-B | -46.87x | -- | HK$11.54B |
06855HKASCENTAGE | -6.23x | 19.11% | HK$10.54B |
07666HKMETIS TECHBIO-P | -24.29x | 96.67% | HK$9.89B |
09606HKDUALITYBIO-B | -5.62x | 85.35% | HK$9.30B |
01952HKEVEREST MED | -145.90x | 326.79% | HK$9.06B |
02616HKCSTONE PHARMA-B | -17.22x | 1.09% | HK$8.31B |
02595HKGENFLEET-B | -5.45x | 66.07% | HK$8.26B |
02493HKMABWELL-B | -6.50x | -- | HK$7.95B |
06938HKRIBOLIFE-B | -37.27x | 29.56% | HK$7.28B |
09887HKLEADS BIOLABS-B | -22.73x | 3.57% | HK$6.99B |
02335HKMICOT PHARMA-B | -16.27x | 37.52% | HK$6.83B |
02171HKCARSGEN-B | -60.42x | 52.33% | HK$6.20B |
09966HKALPHAMAB-B | -27.37x | -- | HK$5.54B |
00775HKCKLIFE SCIENCES | -79.47x | -- | HK$5.14B |
01672HKASCLETIS-B | -7.25x | 78.53% | HK$4.94B |
02256HKABBISKO-B | -9.05x | 814.43% | HK$4.86B |
01779HKLONGBIO-B | -18.23x | -- | HK$4.54B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
